Compare · HBIO vs TXG
HBIO vs TXG
Side-by-side comparison of Harvard Bioscience Inc. (HBIO) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HBIO and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $9.43B, about 249.3x HBIO ($37.8M).
- TXG has been more active in the news (9 items in the past 4 weeks vs 2 for HBIO).
- TXG has more recent analyst coverage (25 ratings vs 2 for HBIO).
- Company
- Harvard Bioscience Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $37.8M
- $9.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2019
- News (4w)
- 2
- 9
- Recent ratings
- 2
- 25
Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest HBIO
- Harvard Bioscience Announces Creation of Scientific Advisory Board
- Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.
- SEC Form 10-Q filed by Harvard Bioscience Inc.
- Harvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Harvard Bioscience Announces Second Quarter 2026 Financial Results
- Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
- Director Eade Katherine A. was granted 16,556 shares, increasing direct ownership by 39% to 58,669 units (SEC Form 4)
- Director Snider William was granted 16,556 shares, increasing direct ownership by 52% to 48,556 units (SEC Form 4)
- Director Denelsky Stephen J was granted 16,556 shares, increasing direct ownership by 79% to 37,556 units (SEC Form 4)
Latest TXG
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
- 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
- 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
- Argus initiated coverage on 10x Genomics with a new price target
- Director Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)
- Chief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)